Kathrine Gamborg Andreassen
Kathrine Gamborg Andreassen was elected Chair of the Board June 2018. Kathrine is an experienced marketing professional and has held various executive positions in Consumer Health and FmCG (Orkla, Kemetyl). She held the position as the Chief Executive Officer at Weifa ASA until the company was acquired by Karo Pharma AB November 2017, and prior to that VP Consumer Health at Weifa AS. She has several years of experience as a consultant in strategy and marketing research . She was also co-owner and the Chair of the Board at Novicus Pharma AS. Gamborg Andreassen studied Business Administration (BBA) at Handelsakademiet/ Oslo Business School and holds a MSc in Business Strategy & Marketing from the University of Wisconsin, Madison.
Toril Marie Ås
Date of birth: 1970
2016- CFO Navamedic ASA
Toril Marie Ås has more than 20 years’ experience of leading finance functions in ICT, media and services industry organizations. Prior to joining Navamedic she has held the position as CFO for Telenor Media Invest, been Finance Director for the Telenor division ‘Corporate Functions and Group Activities’ and been serving at several boards like Amedia, RiksTV, Norges Television, Tv2 Zebra, HMS Norge. Toril holds a MSc in Business from Bodø Graduate School of Business and a MSc in Management from London Business School.
Ole Henrik Eriksen
Position: COO, Business Development
Ole Henrik Eriksen has extensive experience from the pharma, biotech, diagnostics and medtech industries. Previous experience includes VP CMC in Nycomed Imaging, VP Business Development in Medinnova, CEO and COO in Clavis Pharma ASA, COO and responsible for Business Development in Weifa ASA and Chairman of Genetic Analysis AS. He was also one of the three founders of Novicus Pharma AS, now acquired by Navamedic ASA. Mr. Eriksen holds a B.Sc. in Organic Chemistry from the Norwegian University of Sciences and Technology in Trondheim.
Position: Chief Scientific Officer
Date of birth: 07.06.1974
2010- CSO Navamedic ASA
Per-Anders has more than 15 years’ experience working in regulatory affairs and management positions in the pharmaceutical industry. Prior to joining Navamedic Per-Anders was working for Sandoz GmbH in Germany as Head of Regulatory Competence Center for Asia-Pacific region. Previous experience includes being Regulatory Affairs Manager for Sandoz in Australia and Nordic Regulatory Affairs Manager for Sandoz/Hexal in Denmark. Per-Anders Elvertrø holds a Master of Science in Biology from Norwegian University of Science and Technology, Trondheim. Mr. Elvertrø holds 30 000 shares in the Company.
Position: CEO Navamedic Medtech AB
Date of birth: 1966
Education: MBA from Kellogg School of Management, Chicago USA.
Magnus Emmoth is one of OM’s three founders. Magnus Emmoth has extensive experience from a career that, as well as spanning the finance sector, also includes leading positions at a number of medtech companies. His experience ranges from early-stage business development to management positions within larger business concerns. Magnus was among other also responsible for the urological division in the Nordics at Covidien.
Mattias von Haartman
Position: Marketing & Sales Director
Date of birth:
Mattias von Haartman has deep knowledge in sales and marketing of pharmaceuticals and medtech as well as documented success in pricing and reimbursement strategies. Mattias has successfully implemented several pricing optimization projects across multiple geographies.
Prior to joining Navamedic, he worked in various positions for Sandoz, H.Lundbeck and Pfizer. Mattias holds a Bachelor degree in Business Administration and studies in Health Economics and Medical Statistics from Gothenburg School of Business.